Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 8;59(10):1789.
doi: 10.3390/medicina59101789.

Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease

Aleksandra Bołdys  1 , Łukasz Bułdak  1 , Mateusz Maligłówka  1 , Stanisław Surma  1 , Bogusław Okopień  1
Affiliations
Review

Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease

Aleksandra Bołdys et al. Medicina (Kaunas). .

Abstract

Metabolic-associated Fatty Liver Disease is one of the outstanding challenges in gastroenterology. The increasing incidence of the disease is undoubtedly connected with the ongoing obesity pandemic. The lack of specific symptoms in the early phases and the grave complications of the disease require an active approach to prompt diagnosis and treatment. Therapeutic lifestyle changes should be introduced in a great majority of patients; but, in many cases, the adherence is not satisfactory. There is a great need for an effective pharmacological therapy for Metabolic-Associated Fatty Liver Disease, especially before the onset of steatohepatitis. Currently, there are no specific recommendations on the selection of drugs to treat liver steatosis and prevent patients from progression toward more advanced stages (steatohepatitis, cirrhosis, and cancer). Therefore, in this Review, we provide data on the clinical efficacy of therapeutic interventions that might improve the course of Metabolic-Associated Fatty Liver Disease. These include the drugs used in the treatment of obesity and hyperlipidemias, as well as affecting the gut microbiota and endocrine system, and other experimental approaches, including functional foods. Finally, we provide advice on the selection of drugs for patients with concomitant Metabolic-Associated Fatty Liver Disease.

Keywords: diabetes; hyperlipidemia; incretins; metabolic-associated fatty liver disease; obesity; pharmacotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Natural history of MAFLD (modified from [6]).
Figure 2
Figure 2
Promising therapeutic options affecting early phases of MAFLD.
See this image and copyright information in PMC

References

    1. Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F., Romero D., Abdelmalek M.F., Anstee Q.M., Arab J.P., et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 2023;2023:101133. doi: 10.1016/j.jhep.2023.06.003. - DOI - PubMed
    1. Lieverse R.J., Jansen J.B.M.J., Masclee A.A.M., Lamers C.B.H.W. Gastrointestinal Disturbances with Obesity. Scand. J. Gastroenterol. 1993;28:53–58. doi: 10.3109/00365529309101576. - DOI - PubMed
    1. Grgurevic I., Podrug K., Mikolasevic I., Kukla M., Madir A., Tsochatzis E.A. Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. Can. J. Gastroenterol. Hepatol. 2020;2020:9181368. doi: 10.1155/2020/9181368. - DOI - PMC - PubMed
    1. Basha A., May S.C., Anderson R.M., Samala N., Mirmira R.G. Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models. Int. J. Mol. Sci. 2023;24:9996. doi: 10.3390/ijms24129996. - DOI - PMC - PubMed
    1. Fernández T., Viñuela M., Vidal C., Barrera F. Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PLoS ONE. 2022;17:e0263931. doi: 10.1371/journal.pone.0263931. - DOI - PMC - PubMed

MeSH terms